Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
3 INNOVATION
Business development activities adding 4 new mid/late stage high
potential medicines
GYROSCOPE
Acquisition
VISION FOR LIFE
GT005: One-time subretinal Ph2 gene therapy
that could transform care for geographic atrophy,
a leading cause of blindness¹
BeiGene
Option
Ociperlimab: Ph3 TIGIT inhibitor with the potential to treat a
wide range of solid tumors; development program includes
6 global trials in lung cancer, ESCC, cervical cancer
W
Opt-in²
MOLECULAR
partners
Ensovibep: Multi-specific Ph2 DARPinⓇ, specifically designed to
block the receptor binding domains of SARS-CoV-2 spike protein
ucb
Co-development / co-commercialization
DLX313 (UCB0599): Potential first-in-class, small molecule,
alpha-synuclein misfolding inhibitor in Ph2 Parkinson's Disease
DARPin - Designed Ankyrin Repeat Protein. 1. Completion of the transaction is subject to customary closing conditions. Novartis and Gyroscope will continue to operate as separate and independent companies until closing. 2. License
Agreement with Molecular Partners signed.
16 Investor Relations | Q4 2021 Results
1 NOVARTIS | Reimagining MedicineView entire presentation